Minnesota's New High-Medical-Need Product List: The 2027 Inventory Obligation Nobody Should Overlook
OCM has identified the medical cannabis products that qualifying retailers will be expected to carry beginning January 1, 2027. For businesses considering a medical endorsement, the new guidance changes the conversation from whether they can enter the medical market to whether they can consistently serve the patients who depend on it.
By Drew Duffy, MHA, FACHE
Founder & Managing Director, CannaPath Regulatory Solutions
Regulatory review: October 19, 2026
For months, Minnesota cannabis businesses considering the medical market have been evaluating what the state's 2027 changes might mean for them. The Legislature created new opportunities for microbusinesses, mezzobusinesses, and retailers to participate in medical cannabis, while restructuring the relationship between the existing medical and adult-use supply chains.
There was, however, an important piece of information missing from those calculations.
Businesses knew that holding a medical cannabis retail endorsement would mean carrying products identified by the Office of Cannabis Management as high medical need. They knew that medical manufacturing endorsements would carry additional production responsibilities. What they did not know was exactly which products OCM would identify.
That changed on October 12, 2026.
OCM published Guidance Memo GM-2026-08, establishing the state's high-medical-need product list. The document identifies specific cannabinoid formulations and methods of administration that medical-endorsed retailers must make available.
For an operator considering a medical endorsement, this guidance belongs in the business plan, the inventory budget, the purchasing strategy, supplier agreements, and operating procedures.
It also illustrates something we have discussed frequently at CannaPath: obtaining authorization to perform an activity and building a business capable of performing that activity are two different accomplishments.
The state is protecting access to products the ordinary market may not supply
To understand the new requirements, it helps to understand why OCM created the list.
Minnesota's 2026 legislation restructures the medical and adult-use cannabis supply chains. Beginning January 1, 2027, the state moves toward a system in which medical and adult-use products can share much of the same cultivation and manufacturing infrastructure, while medical-specific requirements remain attached to appropriate products, endorsements, and patient transactions.
That creates efficiencies, but it also raises a legitimate concern.
An ordinary adult-use cannabis business generally makes purchasing and production decisions based on customer demand, product availability, and financial considerations. Products that sell quickly tend to receive more shelf space. Products with limited demand may disappear from inventory.
That approach can become problematic when the customer is a medical cannabis patient who depends on a particular formulation or administration method.
Some patients cannot use inhalable products. Others may require a product with a high proportion of cannabidiol, commonly known as CBD. Some need formulations that allow administration without swallowing a traditional pill, while others require higher THC dosages than products commonly available in the adult-use market.
A product that serves a relatively small patient population may not be particularly attractive to a manufacturer concentrating on the largest adult-use market segments.
OCM's high-medical-need designation is intended to address that problem.
The agency explains that it developed the list using input from patients, caregivers, health care practitioners, and cannabis businesses. It also reviewed medical cannabis use patterns, patient priorities, purchasing information, and complaints concerning product availability.
The result is a set of products the agency considers important to patient access and potentially underserved by the broader cannabis market.
The list does not try to name every product a medical cannabis patient might find useful. OCM says it left off many products patients rely on because it expects the streamlined market to keep them available. What remains are the products it believes need protection against disappearing from the market.
What OCM actually requires
The October 12 guidance establishes four formulation categories and several administration methods.
The first category consists of CBD-only products. OCM requires medical-endorsed retail locations to carry both an enteral product in the form of a water-soluble cannabinoid multiparticulate or oral solution or suspension, and an oromucosal product such as an orally dissolvable product or tincture.
The second category consists of products with a high CBD ratio. OCM defines this category as having a THC-to-CBD ratio of 1:15 or greater CBD. As with CBD-only products, medical retailers must carry both the specified enteral and Oromucosal product types.
The third category consists of balanced formulations with a 1:1 THC-to-CBD ratio. For these products, the requirement is broader. Retail locations must carry an enteral pill, an enteral water-soluble multiparticulate or oral solution or suspension, and an oromucosal product.
The fourth category consists of high-THC-dosage products containing at least 20 milligrams of THC per serving, with CBD content that does not exceed the THC content. For this category, the retailer must carry at least one of the three specified administration options: a pill, an enteral water-soluble multiparticulate or oral solution or suspension, or an oromucosal product.

Source: OCM Guidance Memo GM-2026-08, October 12, 2026.
There is an important difference between that last category and the preceding three.
For the CBD-only, high-CBD, and balanced categories, OCM identifies specific product types that must each be carried. For the high-THC category, the guidance permits a choice among the identified administration methods.
Taken together, the guidance establishes eight required formulation-and-administration combinations for a medical-endorsed retail location, with some flexibility in how the high-THC requirement is satisfied.

Counted per retail location. Source: OCM Guidance Memo GM-2026-08.
OCM also specifies that the products may be of any dosage where the guidance does not establish a particular dosage threshold.
One more detail in the memo affects where these products can come from. As of this writing, none of the product types on the list are approved adult-use product types. OCM states that this means they can only be manufactured and sold by businesses with a medical endorsement, and only sold to medical cannabis patients.
These distinctions are worth understanding before a business begins placing orders. Purchasing several products that fall into the same formulation category does not necessarily satisfy the requirement to carry products across the specified administration methods.
The obligation is more complicated than placing an initial order
Imagine a Minnesota cannabis retailer preparing to obtain a medical cannabis retail endorsement in January.
The owner has already identified suppliers, developed a purchasing budget, and decided which adult-use products will remain central to the business. The medical endorsement appears attractive because it creates an opportunity to serve registered patients and potentially expand the company's market.
After reviewing the new guidance, the owner identifies the required high-medical-need products and purchases the appropriate inventory.
At opening, everything is available.
Three weeks later, one of the required formulations sells out.
The supplier is temporarily unable to replace it.
The store continues operating, and the manager places another order. From an ordinary retail perspective, this is a familiar inventory problem. Products occasionally sell out, and businesses reorder them.
But the medical endorsement introduces a different regulatory consideration.
Under the 2026 law, beginning January 1, 2027, OCM can take enforcement action against a business that fails to make a designated high-medical-need product available at a retail location within 24 hours of a patient request. That action can include suspending or revoking the medical cannabis endorsement.
Administrative orders, product embargoes, and civil penalties are also available to the agency.
That does not mean every temporary inventory shortage automatically results in suspension. The law grants OCM enforcement discretion. Nevertheless, the 24-hour provision creates a meaningful operational expectation that businesses should incorporate into their inventory planning.
A store cannot treat required medical inventory exactly like an optional adult-use product line.
The business needs a reliable way to monitor availability, identify shortages, respond to patient requests, and coordinate replenishment.

The 24-hour window is set by law. The four steps are a CannaPath illustration, not an OCM-prescribed process.
That is where the new guidance begins affecting ordinary business operations.
Medical inventory introduces a different kind of purchasing decision
One of the more difficult realities for a small cannabis business is that inventory consumes cash before it generates revenue.
An operator purchasing adult-use products can evaluate sales history, customer preferences, and product margins to determine how much inventory to carry.
Required medical products introduce another consideration: availability may matter even when demand is relatively limited.
A product might sell infrequently but still be important to the patients who need it.
That does not mean businesses should purchase unlimited quantities or allow products to expire on the shelf. It means the purchasing strategy needs to account for the regulatory obligation as well as ordinary commercial demand. And because these products can only be sold to registered patients, a slow-moving item cannot be cleared out to adult-use customers before it expires.
Supplier reliability becomes particularly important.
If a business depends on a single manufacturer for a required formulation, what happens when that manufacturer experiences a production delay? What happens when testing takes longer than expected? What happens when a shipment is rejected, recalled, or delayed?
The pool of possible suppliers is also smaller than it is for adult-use products, since only manufacturers holding a medical endorsement can make what is on the list.
None of this should keep a business out of the medical market. It should put a supply chain review ahead of accepting the obligations attached to a medical endorsement.
An operator considering the endorsement should discuss product availability with prospective suppliers, understand realistic replenishment timelines, and establish a procedure for responding when required inventory becomes unavailable.
Nobody can predict every possible disruption. The point is to avoid discovering, in the middle of one, that the business never established a response process.
Manufacturers have obligations too
The October 12 guidance is not limited to retail businesses.
Minnesota's new medical cannabis manufacturing endorsement also carries obligations concerning high-medical-need products.
OCM states that businesses holding the endorsement must manufacture high-medical-need products.
This is an important consideration for microbusinesses and mezzobusinesses evaluating the additional manufacturing capacity available under the 2027 framework.
An operator may be attracted to the opportunity to increase production capacity but should also consider whether the facility has the equipment, expertise, procedures, and supply arrangements necessary to manufacture products within the designated medical categories.
Manufacturing an oral solution is not necessarily the same operational undertaking as manufacturing a conventional adult-use edible. Different formulations and administration methods can require different equipment, quality controls, production processes, and validation considerations.
The endorsement is an operational commitment as much as a production-capacity benefit, and it should be evaluated that way.
There is also a distinction between the manufacturing and retail obligations that deserves careful attention.
OCM's guidance explicitly identifies the product types that each medical-endorsed retail location must carry. It also states that medical-endorsed manufacturers must manufacture high-medical-need products. Businesses should not automatically interpret those statements as requiring every individual manufacturer to produce every listed formulation.

Sources: OCM Guidance Memo GM-2026-08; OCM, 2026 Legislative Changes to Chapter 342.
The precise manufacturing obligations applicable to a proposed operation should be confirmed against the statutory requirements, OCM's implementation instructions, and the business's approved endorsements before committing to a production plan.
This is where SOPs become particularly important
A medical cannabis retailer may already have a well-developed inventory control procedure.
That procedure may describe receiving, storage, reconciliation, product transfers, damaged inventory, and inventory adjustments.
But does it address required medical inventory?
Does it establish how employees identify products designated as high medical need? Does it explain how availability is monitored? Does it identify who responds when a required product becomes unavailable?
More importantly, does it establish how the business handles a patient request when the requested product is not immediately available?
A business could have an otherwise excellent inventory procedure and still be missing the controls necessary to support its medical endorsement.
The entire inventory system probably does not need to be rewritten. The procedure does need to be reviewed against the new obligations.
A useful starting point is to compare the October 12 product list against the company's proposed inventory categories and purchasing arrangements. The business should then determine how it will monitor availability at each location and document its response to shortages.

Questions drawn from this article. A starting point for review, not an OCM checklist.
Employee training should reflect the same process.
Staff should understand which products are required, how medical inventory differs from ordinary adult-use inventory, and when a situation needs to be escalated to management or the appropriate medical cannabis professional.
The written procedure, purchasing system, employee responsibilities, and actual operation should all describe the same process.
Where CannaPath can help
For CannaPath, this is precisely the kind of regulatory development that demonstrates why compliance planning should happen before a business expands.
The medical endorsement may be financially attractive. It may also allow a business to serve patients who have had limited access to appropriate products.
But the decision should be based on the complete operating responsibility.
CannaPath can help businesses evaluate the documentation, inventory controls, training requirements, and operating procedures associated with medical endorsements. Where questions involve legal interpretation or authorization, appropriate legal review or clarification from OCM remains important.
Businesses can also begin much of this work themselves.
Review the new product list. Speak with suppliers. Evaluate whether the proposed operation can maintain the required inventory. Determine how shortages will be handled, and make sure those responsibilities appear in the company's procedures.
Scout™ can help identify gaps in submitted policies and supporting documentation, while a broader operational review can examine whether the business is prepared to carry out those procedures in practice. Minnesota's medical cannabis market is entering a new phase.
The October 12 guidance gives operators something they did not previously have: a defined set of product-availability expectations against which to evaluate their plans.
That is useful information, even for businesses that ultimately decide not to pursue a medical endorsement.
Entering the medical market means accepting responsibility for making those products available to patients who may depend on them.
And that responsibility deserves to be understood before the endorsement is obtained.
I get it, folks. This is a lot of information to take in, but I promise you, it is doable. And honestly, we have some of the best clients anyone could ask for.
In fact, at the suggestion of several of those clients, we're going to try something new. And the best part? It's completely free.
We genuinely want to see every one of you succeed, so we're introducing something we're calling CannaPath Sunday Meetings.
Here's how it's going to work.
Starting now through October 30th, we'll be accepting questions from Minnesota cannabis business owners. These can be questions about compliance, day-to-day operations, or those situations where you're simply wondering, "How the heck is everyone else handling this?"
We'll then share those questions with some of our experienced store owners who have volunteered to participate. They'll provide their perspectives, share what's working in their businesses, and offer some practical insight from the people actually doing this every day.
Our team will review those responses for accuracy, and on Sunday, November 1st, I'll host a Microsoft Teams meeting for everyone who has signed up. We'll walk through the questions, discuss the answers, and hopefully help everyone walk away with a little more confidence and a few less headaches.
And we're not stopping there.
For our next Sunday meeting, our legal team has generously agreed to make themselves available to address submitted questions. We'll share more details about that session as we get closer.
Want to join us?
Simply send an email to clientservices@cannapath.org with "Sunday Meetings" in the subject line, and we'll make sure you're included. You can also send along any questions you'd like us to consider.
And one last thing, because this matters to us.
As with everything we do at CannaPath, signing up does not mean you're signing up for a marketing campaign. We won't add you to some unrelated mailing list, bombard you with sales pitches, or sell your information to anyone.
We don't have time for that, and quite frankly, neither do you.
This is simply an opportunity for Minnesota cannabis business owners to learn from one another, get some practical answers, and maybe even enjoy a Sunday afternoon together.
Because sometimes the best resource we have is each other.
-Drew
Primary Sources
Minnesota Office of Cannabis Management, Guidance Memo GM-2026-08, High-Medical-Need Product List, October 12, 2026.
Minnesota Laws 2026, chapter 123, sections 97, 98 and 102 (Minnesota Statutes § 342.51, subdivisions 1c, 1d and 6) and section 103 (Minnesota Statutes § 342.515).
Minnesota Office of Cannabis Management, 2026 Legislative Changes to Chapter 342.
Regulatory review: October 19, 2026.
This article provides general regulatory and operational information, not legal advice. OCM has said it will continue to evaluate patient access and product availability, and the list may change. Verify current requirements with OCM before making purchasing or production decisions



